Advanced cystic lung cancer complicated with pulmonary lymphangitic carcinomatosis: a case report Authors: Huizhen Tang, Jiayi Zhou, Tianning Tian, Haolin Guan, Liang Ye Published: 2026 ABSTRACT Pulmonary lymphangitic carcinomatosis (PLC) is a life-threatening complication of intrathoracic malignant tumors and is characterized by tumor cell spread via the pulmonary lymphatic system. The lymphatic vessel dilation, interstitial thickening and edema caused by the tumor can lead to progressive breathing difficulties, which is a typical clinical feature of this condition. Pleuritic pain may occur if subpleural lymphatics are obstructed, but clinical manifestations are often non-specific. Most patients are diagnosed at an advanced stage with respiratory failure, and there is no definitive therapy; thus, the overall prognosis remains poor with short survival. Herein, we report a case of advanced cavitary lung adenocarcinoma complicated with PLC, with pericardial effusion and mediastinal or pericardial metastases. The patient underwent palliative surgery followed by sequential chemotherapy and immunotherapy and had survived for 41 months as of the last follow-up.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13019-026-04299-z. Introduction Lung cancer ranks first in China in terms of both incidence and mortality. Non-small cell lung cancer (NSCLC) is the predominant pathological subtype, accounting for approximately 85% of all lung cancer cases, and is histologically categorized into squamous cell carcinoma (SQC), adenocarcinoma (ADC), and large cell carcinoma [1–2]. Small-cell lung cancer (SCLC) is a high-grade neuroendocrine lung malignancy that accounts for 10%–15% of all lung cancer cases [3]. It is characterized by high malignancy, and is often diagnosed at an advanced stage with rapid disease progression [4]. Lung cancer associated with cystic airspaces (LCCA) is a relatively rare subtype of lung cancer, with its detection rate increasing annually. Radiologically, cystic air-filled spaces are present within or adjacent to the tumor lesion and often coexist with ground-glass or solid components. It is easily confused with inflammation, infectious lesions, pulmonary bullae, and tuberculosis; missed diagnosis or misdiagnosis may lead to delayed treatment and poor prognosis [5]. Pulmonary lymphangitic carcinomatosis (PLC) accounts for 6% to 8% of metastatic lung cancers [6]. Its pathophysiological mechanism remains unclear, but it may be associated with direct invasion, lymphatic circulation, and hematogenous dissemination.Tumor cells induce lymphatic dilation and interstitial thickening, which manifested as marked lymphatic dilatation, vascular wall edema, fibrosis, inflammatory cell infiltration, extensive tumor emboli in intrapulmonary lymphatics and small blood vessels, and proliferation of pulmonary interstitial connective tissue [7–8]. The case reported in this paper was misdiagnosed as pulmonary infection and tuberculosis in another hospital. Upon admission to our hospital, the patient had massive pericardial effusion and poor cardiopulmonary tolerance, which made him unable to tolerate aggressive systemic chemotherapy. After receiving palliative surgery for symptom relief, individualized chemotherapy and immunotherapy were subsequently successfully implemented. Case report A 63-year-old male patient was admitted to the hospital because of “discovery of a right lung mass for 3 months”. From March 21, 2022 to May 7, 2022, the patient had been treated in a local hospital for “dyspnea on exertion for several years, aggravated for 3 weeks”. On March 29, 2022, chest CT revealed tuberculous nodules in the upper lobe of the right lung, pericardial effusion, and a small amount of pleural effusion on the right side. An external hospital diagnosed a middle lobe infection of the right lung, and performed pleural effusion puncture and catheter drainage, pericardial puncture and catheter drainage. After anti-infection treatment with aztreonam and moxifloxacin, the dyspnea was significantly relieved, but was accompanied by orthopnea; thus, he was transferred to our hospital for further treatment. He was admitted to our hospital on May 7, 2022, for continuous treatment. Past history: The patient had a history of hypertension and was treated orally with irbesartan tablets and bisoprolol fumarate tablets orally; he had a history of diabetes and self-injection of insulin aspart, and he had a history of infectious tuberculosis. Physical examination at admission revealed a temperature of 36.7℃, heart rate of 120 beats/min, respiratory rate of 28 breaths/min, blood pressure of 113/80 mmHg (1mmHg = 0.133 kPa), peripheral oxygen saturation of 87%, clear consciousness, and listlessness. Examinations Chest CT: Chest CT on May 7,2022 (No.001265421) revealed the following findings: (1). Cystic lung cancer under the pleura of the apical segment of the right upper lobe, multiple enlarged lymph nodes in the mediastinum and right hilum, thickening of the axial interstitium of the right lung, considering lymphangitic carcinomatosis, and pleural effusion on both sides were considered; (2). Local wall calcification of the aorta and coronary arteries, and pericardial effusion; (3). Local fat mass in the right axilla was accompanied by enlarged lymph nodes. Positron Emission Tomography/Computed Tomography(PET/CT): (1). An irregular cavity in the right upper lobe with eccentric cyst wall thickening and increased metabolism was observed, suggesting the presence of cystic lung cancer (Fig. 1A); thickening of the axial interstitium of the right lung, especially in the middle and lower lobes of the right lung, indicating the preaence of lymphangitic carcinomatosis (Fig. 2); the presence of multiple hypermetabolic lymph nodes in the bilateral hilar, mediastinum, and cardiophrenic angle and above the diaphragm; and a small amount of pleural effusion on both sides. (2). Pericardial effusion and multiple calcifications in the aortic and coronary artery walls (Fig. 3A). (3). Thyroid enlargement with increased glucose metabolism; multiple lymph nodes in the bilateral neck, supraclavicular fossa and axilla, and increased glucose metabolism. Diagnosis On the basis of clinical symptoms, medical history, laboratory tests, chest CT, PET/CT findings, and pathological results, the following diagnoses were made: (1). A malignant tumor of the upper lobe of the right lung (pT3N2M1a, Stage ⅣA) was detected. According to the 8th edition of the tumor-node-metastasis (TNM) staging system, pathological examination of the present case indicated tumor invasion of the pleura and pericardium, which was consistent with the T3 stage. One lymph node (1/1) was identified in the anterior mediastinal tissue with metastatic carcinoma, corresponding to the N2 stage. The presence of tumor nodules in the pleura or pericardium and malignant pericardial effusion classified the disease as M1a. When T3 was combined with M1a or any N category, the clinical stage was determined to be IVA. (2).Pulmonary lymphangitic carcinomatosis (PLC) was diagnosed on the basis of the findings of chest CT and PET/CT; (3). Secondary malignant tumor of the pericardium; (4). Pericardial effusion; (5). Bilateral pleural effusion; (6). Colorectal polyps; (7). A personal history of tuberculosis; (8).Hypertension (Grade 2);(9). Type 2 diabetes mellitus. Treatment and follow-up The patient was in poor condition upon admission and was given electrocardiographic monitoring and high-flow oxygen therapy to stabilize vital signs. After the relevant examinations were completed, a multidisciplinary consultation (MDT) was conducted involving departments of respiratory medicine, critical care medicine, anesthesiology, and pathology. It was determined that the patient could not tolerate radical lobectomy because of extensive metastasis and poor cardiopulmonary function; thus, palliative palliative surgery was selected. On May 25, 2022, the patient underwent video-assisted thoracoscopic right upper lobe wedge resection+pericardial windowing+pleural and pericardial biopsy+intercostal nerve block under combined intravenous-inhalation anesthesia. Intraoperatively, the pericardium was distended and taut, containing copious pale red hemorrhagic fluid Fig. 3B; multiple white miliary nodules were adherent to the visceral pericardium Fig. 3C. The pleura was slightly thickened, and a small amount of fibrinous exudate was present. The tumor mass in the right upper lobe was palpable, with obvious depression signs of depression on the surface Fig. 1B. After the operation, the patient was transferred to the intensive care unit for close monitoring, with continuous electrocardiographic monitoring, high-flow oxygen inhalation, and symptomatic support treatment (including anti-infection therapy, fluid replacement, and nutritional support). The patient’s vital signs gradually stabilized, and no obvious complications such as bleeding or infection occurred. Postoperatively, the patient received regular systemic chemotherapy combined with immunotherapy.During the follow-up period, the patient’s symptoms significantly improved, and no severe adverse reactions such as immune-related colitis or skin rash occurred.Regular reexaminations (chest CT, routine blood tests, and biochemical indicators) revealed no obvious progression of the tumor, and the patient’s quality of life significantly improved. Pathology revealed the following results (No.2022–03518):(right upper lobe of the lung) adenocarcinoma, which was mainly solid (accounting for approximately 80%), with a small amount of micropapillary and acinar components and was accompanied by intravascular tumor emboli and pleural invasion; (pericardium, pleura) tumor metastasis was found in the examined tissues, and tumor cells were scattered in the lymphatic vessels; and (pericardial fat tissue) lymph node metastasis was found (1/1). The immunohistochemical results were as follows: CK7(+), TTF-1(+), D2-40(+), extensive intravascular tumor emboli), Ki-67(5%+), and PD-L1(TPS 50%+). PD-L1 expression level: D The patient was positive for PD-L1 expression, with a tumor proportion score (TPS) of 55% Fig.4. Molecular detection results: Common driver gene tests, including those for EGFR, ALK, and ROS1, were completed, and all the results were negative. After the operation, the 1st to 6th courses of chemotherapy were administered on June 1, 2022, July 1, 2022, July 28, 2022, August 25, 2022, September 22, 2022, October 14, 2022, respectively. The chemotherapy regimen was formulated as follows:800 mg pemetrexed administered intravenously on day 1, combined with 500 mg carboplatin administered intravenously on day 1. The 1st to 4th courses of immunotherapy were conducted on June 8, 2022, July 4, 2022, July 26, 2022, August 23, respectively, with 200 mg of pembrolizumab as the therapeutic agent. On September 15, 2022,the patient developed hematochezia. Colonoscopy performed on September 20, 2022 revealed proctosigmoiditis accompanied by erosion. The cause of bleeding was considered to be colitis. After consultation and discussion with the medical oncology department, this adverse reaction was determined to be related to the immunotherapeutic drug. Therefore, the 5th course of immunotherapy was temporarily suspended to observe and evaluate the improvement in hematochezia after drug withdrawal. After drug withdrawal, the patient still had a small amount of hematochezia. To alleviate the adverse reactions to immunotherapy, the patient was admitted to the hospital for standardized treatment: methylprednisolone sodium succinate was administered intravenously to suppress the abnormal immune response, and symptomatic support measures were given simultaneously. After the symptoms improved, the patient was discharged and switched to oral methylprednisolone tablets for maintenance treatment. Gradually, the hematochezia was relieved and completely resolved. To date, the patient has been under regular follow-up, remains alive, and maintains a stable general condition without obvious tumor progression Fig. 5. Fig. 1Primary tumor lesion. (A) On chest CT, an irregular cavitary lesion is visible in the apical segment of the right upper lung lobe. The local wall of the cavity shows irregular nodular thickening, with adjacent pleural retraction. (B) Anthracotic deposition on the surface of the right lung, with obvious depression observed. Small new tissue masses are visible around the depression, protruding beyond the visceral pleura. Primary tumor lesion. (A) On chest CT, an irregular cavitary lesion is visible in the apical segment of the right upper lung lobe. The local wall of the cavity shows irregular nodular thickening, with adjacent pleural retraction. (B) Anthracotic deposition on the surface of the right lung, with obvious depression observed. Small new tissue masses are visible around the depression, protruding beyond the visceral pleura. Fig. 2CT Signs of Lymphangitic Carcinomatosis of the Lung. There was axial interstitial thickening (predominantly in the right middle and lower lobes of the lung), interlobular septal thickening, lymphangitis with impaired lymphatic drainage, and bilateral pleural effusion. CT Signs of Lymphangitic Carcinomatosis of the Lung. There was axial interstitial thickening (predominantly in the right middle and lower lobes of the lung), interlobular septal thickening, lymphangitis with impaired lymphatic drainage, and bilateral pleural effusion. Fig. 3Pericardial lesions. (A) CT signs of pericardial effusion. (B) After pericardiotomy (pericardial opening), serosanguineous fluid was observed to have gushing out. (C) Multiple white millet-like particles were observed within the pericardial cavity Pericardial lesions. (A) CT signs of pericardial effusion. (B) After pericardiotomy (pericardial opening), serosanguineous fluid was observed to have gushing out. (C) Multiple white millet-like particles were observed within the pericardial cavity Fig. 4Immunohistochemical findings of lung adenocarcinoma. PD-L1 immunohistochemical staining of lung adenocarcinoma tissue, original magnification,×200. The tumor cell membranes showed brownish-yellow staining, indicating positive PD-L1 expression (high TPS) Immunohistochemical findings of lung adenocarcinoma. PD-L1 immunohistochemical staining of lung adenocarcinoma tissue, original magnification,×200. The tumor cell membranes showed brownish-yellow staining, indicating positive PD-L1 expression (high TPS) Fig. 5Chest computed tomography performed at the last follow-up on October 27, 2025. This study was approved by the Ethics Committee of Shanghai Seventh People’s Hospital, with the approval number: 2023-7th-HIRB-058, and the informed consent was obtained from the patient. Chest computed tomography performed at the last follow-up on October 27, 2025. This study was approved by the Ethics Committee of Shanghai Seventh People’s Hospital, with the approval number: 2023-7th-HIRB-058, and the informed consent was obtained from the patient. Discussion Lymphangitic carcinomatosis (PLC) is a relatively dangerous intrathoracic metastasis pattern of advanced malignant tumors and is clinically characterized by progressive dyspnea and hypoxemia. There is no specific treatment plan, and the overall prognosis is poor, with a median survival period of usually only several weeks to months [9–10]. Although cystic lung cancer has an atypical morphology, it is highly invasive and can spread rapidly through both the lymphatic and serosal cavity pathways, necessitating high clinical vigilance. In this case, the patient developed PLC, extensive pericardial metastasis, and a large amount of malignant pleural effusion during disease progression. Palliative surgery was performed to relieve acute symptoms and clarify the diagnosis, and survival was achieved after combined chemotherapy and immunotherapy. The diagnosis and treatment process of this case has certain clinical implications. In the early stage of PLC, chest X-ray reveals no obvious abnormalities. With the progression of the disease, reticular nodular changes can be seen in the lower lobes.In the early stage, chest CT can reveal “interstitial lesions, linear and reticular shadows, and thickened interlobar fissures”. In the advanced stage, CT indicates “irregular thickening of tracheovascular bundles and interlobular septa, as well as multiple beaded nodules of varying sizes less than 3 mm in diameter distributed along the interlobular septa and pleura”. Axial and peripheral subpleural interstitial nodular thickening on CT is a typical feature [11–12]. PET/CT can not only reveal interstitial metabolism but also display its morphological signs, which is highly valuable for the diagnosis of PLC [13]. PET/CT remains the cornerstone of staging and can comprehensively evaluate metabolically active lung lesions, lymph nodes, and distant metastatic lesions.In our case, PET /CT was used as an auxiliary examination to confirm PLC and revealed pathologically high metabolic uptake in multiple suspected metastatic sites, including the bilateral hilar and mediastinum. Primary lung cancer combined with massive malignant pericardial effusion can rapidly lead to respiratory failure and cardiac tamponade, which is a type of tumor emergence. When the patient was admitted to the hospital, they presented with severe hypoxemia, tachycardia, and a large amount of pericardial effusion, and the condition was critical. For patients in the advanced stage with critical conditions, radical surgery is difficult to implement, and simple conservative treatment often fails to alleviate symptoms or determine the pathological type, thereby delaying systemic treatment. Such cases are characterized by rapid disease progression, multiple organ involvement, and high difficulty in management. If not handled properly, they can lead to death within a short period.The successful diagnosis and treatment of this patient provide an important reference for such high-risk phenotype cases. In this case, palliative surgeries, including thoracoscopic wedge resection, pericardial fenestration, and pleuropericardial biopsy, were performed, which solved the following problems: (1) quickly relieve cardiac tamponade, improve hypoxemia and cardiopulmonary function, and stabilize vital signs; (2) clarify the pathological diagnosis, determine the nature of the lesion, and simultaneously screen for lymph nodes and distant metastases; (3) and provide a basis for the formulation of subsequent chemotherapy and immunotherapy regimens. During treatment, symptoms such as immune-related hematochezia were observed, which were relieved after glucocorticoid intervention, and did not affect the overall treatment process. These findings suggest that immune-related adverse reactions can be controlled and managed through the rational application of relevant drugs. Analysis of the molecular characteristics of tumor cells is a key step in the treatment of lung adenocarcinoma.In this case, the patient was negative for driver genes (EGFR/ALK/ROS1) but had high PD-L1 expression (TPS 55%). The combination of pemetrexed-platinum drugs and pembrolizumab has significant therapeutic benefits and is a first-line treatment option for advanced non-small cell lung cancer [14–15]. After the operation, the patient was treated with a regimen of pemetrexed combined with carboplatin and pembrolizumab. The tumor was well controlled within a short period of time. Despite the disease being at an advanced stage, the patient still achieved a relatively long survival period. During the treatment, there was hematochezia was considered to be immune-related. The symptoms were relieved after treatment with glucocorticoids and did not affect the overall treatment process. These findings suggest that immune-related adverse reactions can be controlled and managed through the rational application of relevant drugs. Conclusion In conclusion, although cystic lung adenocarcinoma complicated with PLC and extensive pericardial metastasis is an advanced and critical condition, we achieved significant symptom relief and relatively prolonged survival through individualized comprehensive treatment combining palliative surgery, chemotherapy, and immunotherapy. Summarizing the experience from the diagnosis and treatment process of this case can improve the clinical understanding of the disease and provide ideas for the diagnosis and treatment of PLC. Electronic Supplementary Material Below is the link to the electronic supplementary material. list of revisions list of revisions